The last weekend of September, oncologists, thoracic surgeons and more gathered in Canada for the World Conference on Lung Cancer. The meeting reviewed new research and potentially practice-changing abstracts. If you missed the conference, check out some highlights from twitter.
People shared snippets from their favorite talks or what they were most stunned by.
Great talk from Dr Colson on surgical advances for lung cancer!!!#wclc18 @IASLC @WomenInThoracic https://t.co/9dWwK8R6v1
— donington (@jdoningtonmd) September 26, 2018
Another Important Debate: Large Cell Neuroendocrine Carcinoma should be Treated like NSCLC or SCLC? More Translational Research Needed! #iaslc #WCLC18 #lungpath #onco @hospitalclinic @NReguart pic.twitter.com/lDT1u1HidL
— Cristina Teixido (@teixido_c) September 26, 2018
#WCLC18 @SylvesterCancer Great debate on Large Cell NEC, to treat like SCC or NSCLC? No clear data, but NGS may be helpful. RB1 WT do better with NSCLC regimens. Also STK11/KEAP1 mutations are about 20-30%, the benefits of IO’s?Early data suggests benefit though
— Dr. Raja Mudad (@DrMudad) September 26, 2018
Here is highlighted the importance of academic programs to limit off label use and assessment of drug efficacy in rare molecular actionnable alterations @MSPneu @IASLC @Institut_cancer @IFCTlung #WCLC18 pic.twitter.com/6Zxt55vwr8
— Fabrice Barlesi (@barlesi) September 25, 2018
Can any drug, or dose of radiation therapy, save this many lives? It’s okay to stop and think about it. #WCLC2018 #VAPALS #lcsm #NELSON https://t.co/Bdi36ihRoZ
— Drew Moghanaki (@DrewMoghanaki) September 27, 2018
But remember that you can always have an Yoda Master in scrubs at the O.R 😉 #WCLC18 #SABR @IASLC pic.twitter.com/XovXa3W8H6
— Vanessa Menezes (@Vanessatorax) September 25, 2018
💨 Radon is a well-known cause of lung cancer.
— Dr. Antonio Calles (@Tony_Calles) September 24, 2018
👉 Interestingly, it may be also related to known targetable oncogenic mutations and gene rearrangements, such EGFR, BRAF, HER2, and ROS1.
👏 Highly proud of @LauraMezquitaMD and her work at @GustaveRoussy #LCSM #WCLC2018 @IASLC pic.twitter.com/9cjAP5uPzG
This was one of the most insightful 'smaller' talks at #WCLC2018 @IASLC Kudos to the authors for presenting this series. https://t.co/Uddfu6BLRS
— Herbert Loong (@herbloong) September 26, 2018
There was also an emphasis on patients.
A final word from #WCLC2018 -- all this great research is irrelevant without access. #lcsm https://t.co/crXqRD8GvX
— Liz Highleyman (@LizCancerHealth) September 26, 2018
Professor Michael Boyer of @COBLH delivers one of the final take home messages of #WCLC2018: “Patients Are Our Partners.” Well said Dr. Boyer! #LCSM pic.twitter.com/kFStE2KBGq
— LCAM (@LCAM_org) September 26, 2018
Especially when the drug keeping you alive costs more than $14k/month! Many patients scramble to cover their copays. #WCLC2018 #WCLC18 #LCSM https://t.co/eHYuiNh2MS
— EGFR Resisters (@EGFRResisters) September 26, 2018
.@myESMO President Elect @peters_solange speaking at #WCLC2018 Plenary, reminding us that developments in #cancer care are only valuable to extent they're available to pts, which varies remarkably around world. Need to get pts everywhere access to best therapy. #CancerGroundshot pic.twitter.com/29kHvSrFXG
— H. Jack West, MD (@JackWestMD) September 24, 2018
Overall, conference-goers thought it was one of the most productive meetings they’ve been to.
4 positive updates of the 5 plenary presentations in #WCLC18 #IASLC This year felt like one of the best years to be in lung cancer. Fantastic conference! Thank you and see you in Barcelona next year!
— S Swarup, MD (@Shri_doctor) September 27, 2018
#WCLC18 @SylvesterCancer What an exciting time in cancer and especially in #LungCancer This picture exemplifies where we were and where we are going. I find it to be very true, not just for TRK, but for more genes in the tentacles pic.twitter.com/UqsPezs9cB
— Dr. Raja Mudad (@DrMudad) September 26, 2018
#WCLC18 @SylvesterCancer I have never been to a meeting where three plenary presentations were practice changing and NEJM publications! #Durvalumab in stage III #NSCLC, #brigatinib in ALK+ first line and #atezolizumab in first line #smallcelllungcancer
— Dr. Raja Mudad (@DrMudad) September 25, 2018
